Cholesterol

Clinical Study

Rosiglitazone and Fenofibrate Additive Effects on Lipids

Table 1

Baseline characteristics and laboratory findings with posttreatment changes.
GroupPlaceboFenofibrateRosiglitazoneCombinedANOVA
𝑁 = 1 0 𝑁 = 9 𝑁 = 8 𝑁 = 7 Rank
Mean ± SDMean ± SDMean ± SDMean ± SD 𝑃 -value
Age 5 7 . 4 ± 1 1 . 1 6 1 . 2 ± 1 1 . 6 5 7 . 3 ± 8 . 4 5 4 . 7 ± 9 . 5
M : F6 : 43 : 65 : 33 : 4
Pre-TG 2 0 6 ± 6 5 2 7 8 ± 1 2 6 2 3 4 ± 5 8 2 3 9 ± 7 3 𝑃 = 0 . 2 1 2
Post-TG 2 0 2 ± 5 3 1 9 2 ± 6 4 2 4 0 ± 1 1 5 1 7 2 ± 2 7
(%Δ) ( 7 . 6 % ± 5 1 . 0 % ) ( − 2 . 2 % ± 2 6 . 0 % ) ( 7 . 4 % ± 4 8 . 9 % ) ( 2 0 . 0 % ± 3 6 . 5 % )
Pre-HDL-C 4 8 ± 9 4 1 ± 8 5 2 ± 1 9 5 2 ± 1 4 𝑃 = 0 . 3 4 2
Post-HDL-C 4 8 ± 9 4 7 ± 7 5 0 ± 1 7 5 3 ± 9
(%Δ) ( 1 . 7 % ± 1 0 . 5 % ) ( 1 4 . 5 % ± 2 1 . 6 % ) ( 1 . 9 % ± 2 4 . 6 % ) ( 5 . 8 % ± 1 6 . 4 % )
Pre-LDL-C 1 2 4 ± 4 6 1 1 1 ± 4 0 1 4 5 ± 2 4 . 6 % 1 0 6 ± 4 1 𝑃 = 0 . 6 9 2
Post-LDL-C 1 2 8 ± 3 9 1 1 8 ± 3 2 1 4 0 ± 4 1 1 0 2 ± 3 1
(%Δ) ( 1 3 . 7 % ± 4 7 . 8 % ) ( 2 . 6 % ± 2 9 . 3 % ) ( − . 5 % ± 2 7 . 4 % ) ( 3 7 . 3 % ± 1 4 1 . 6 % )
± pre-Tot C 2 0 4 . 4 ± 5 7 . 9 2 1 3 . 6 ± 3 9 . 0 2 3 8 . 4 ± 3 9 . 5 2 1 5 . 7 ± 3 6 . 6 𝑃 = 0 . 3 7 2
Post-Tot C 2 2 7 . 4 ± 3 7 . 2 1 9 9 . 0 ± 5 1 . 2 2 3 0 . 9 ± 5 2 . 2 2 0 1 . 1 ± 3 6 . 5
(%Δ) ( 2 5 . 8 % ± 7 0 . 2 % ) ( − 7 . 7 % ± 2 6 . 1 % ) ( − 2 . 3 % ± 2 1 . 3 % ) ( − 5 . 0 % ± 2 1 . 6 % )